Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
Journal of Oncology Practice
|
July 2, 2010
Negotiating for success: navigating the contracting process for an exemplary research program
Allison R Baer, John A Hohneker, Teresa L Stewart, et al.
The Journal of Supportive Oncology
|
June 30, 2006
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial
Stephen H Rosenoff, Nashat Y Gabrail, Richard Conklin, et al.
Critical Reviews in Oncology/Hematology
|
March 6, 2007
Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006
Richard Weitzman, Nicholas Sauter, Erik Fink Eriksen, et al.
The Oncologist
|
November 25, 2004
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy
Charles L Vogel, Ronald H Yanagihara, Albert J Wood, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
Journal of Oncology Practice
|
July 2, 2010
Negotiating for success: navigating the contracting process for an exemplary research program
Allison R Baer, John A Hohneker, Teresa L Stewart, et al.
The Journal of Supportive Oncology
|
June 30, 2006
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial
Stephen H Rosenoff, Nashat Y Gabrail, Richard Conklin, et al.
Critical Reviews in Oncology/Hematology
|
March 6, 2007
Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006
Richard Weitzman, Nicholas Sauter, Erik Fink Eriksen, et al.
The Oncologist
|
November 25, 2004
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy
Charles L Vogel, Ronald H Yanagihara, Albert J Wood, et al.
Page
of 1